Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250042/S002

BAGUERAC Cervical Disc Prosthesis

Spineart USA, Inc. · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONP250042/S002

What did the FDA approve?

Spineart USA, Inc. submitted a post-approval study protocol for the BAGUERA C Cervical Disc Prosthesis under supplement S002 to PMA P250042. The FDA database records the decision as APPR and lists the supplement type as Normal 180 Day Track No User Fee, with the supplement reason given as Postapproval Study Protocol.

The statement indicates the protocol was submitted to comply with conditions of approval in the approval order for P250042. The record does not include the protocol contents, study endpoints, enrollment targets, or any safety or effectiveness findings. The submission of a protocol is distinct from evidence that the device is safe or effective.

FDA approval order statement

requested approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250042
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Orthopedic
Decision date
Sep 22, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250042/S002
Regulatory pathway
PMA supplement
Product code
MJO
Decision code
APPR
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, intervertebral disc.

Product code
MJO
FDA device class
3

For the original device and its historical approval scope, see PMA P250042. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250042 · Original PMA

    BAGUERAC Cervical Disc Prosthesis

  2. P250042/S002 received

    Application receipt date recorded by FDA.

  3. P250042/S002 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P250042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250042

Product / regulatory recordCompanyPathwayDecision dateSource
Spineart USA, Inc.PMA approvalAug 10, 2026FDA

Explore the linked device profile

Other records with product code MJO

Product / regulatory recordCompanyPathwayDecision dateSource
Synergy DiscP250028/S003
Synergy Spine Solutions, Inc.PMA supplementSep 17, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
Highridge Medical, LLCPMA supplementSep 16, 2026FDA
prodisc C NovaP070001/S031
Centinel Spine, LLCPMA supplementSep 9, 2026FDA
Synergy Spine Solutions, Inc.PMA approvalFeb 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Spineart USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
23332 Mill Creek Dr., Suite 150, Laguna Hills, CA, 92653

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records